with discrete onset of symptoms (e.g., fatigue, abdominal pain, loss of appetite, and intermittent nausea) and jaundice or elevated serum aminotransferase levels, plus detectable levels of IgM antibody to HAV (IgM anti-HAV) [3] . Presence of IgM anti-HAV is considered to be both highly sensitive and highly specific to the diagnosis of hepatitis A [1, 4] . Case patients without laboratory-confirmed infections are considered to have confirmed cases if they are epidemiologically linked to a laboratory-confirmed case [3] .
From January 2002 through February 2005, there were 28 cases of hepatitis A that met the case definition reported to the Alaska Section of Epidemiology. However, 13 additional cases were reported in persons who had test results positive for IgM anti-HAV but did not demonstrate clinical or epidemiological profiles consistent with a diagnosis of hepatitis A. These persons were considered to have possible false-positive test results for IgM anti-HAV. We reviewed additional medical and epidemiological information from these 13 persons to determine whether they had common epidemiologic, clinical, or laboratory findings.
Results. The median age of the 13 persons with possible false-positive IgM anti-HAV test results was 60 years (range, 9-77 years; see table 1), compared with 41 years (range, 18-77 years) among patients who met the case definition for hepatitis A. Eight of the 13 persons were male; 3 were white, 3 were Alaska Native, 2 were Asian, and 5 had no race specified.
Eight persons had laboratory abnormalities indicating liver inflammation or dysfunction, including 4 who had a clinical illness. Only person C had an acute onset of symptoms, which began after an acetaminophen overdose. She was tested for IgM anti-HAV as part of an evaluation of abnormal aminotransferase concentrations following her ingestion of acetaminophen. Her aminotransferase concentrations had declined to near normal in a serum specimen obtained 4 days later, after treatment for the overdose, which suggested that acetaminophen intoxicationrather than HAV infection-was the cause of the elevated aminotransferase concentrations. Persons A, E, and G were symptomatic but had histories of ongoing liver disease or inflammation due to other causes over periods of weeks to months; only person G was jaundiced. Four persons (F, I, J, and M) were tested for IgM anti-HAV to evaluate the cause of elevated aminotransferase concentrations but had no symptoms of hepatitis A. Five persons (B, D, H, K, and L) did not have any clinical or laboratory evidence of hepatitis A. The reasons for testing given by the health care providers for all 13 persons are listed in table 1.
Testing was performed by 4 different laboratories, and no . Although reflex testing is appropriate for persons with acute hepatitis, it can yield false-positive results when used for screening. Six persons described in this review underwent IgM anti-HAV testing only because of routine reflex testing; all but 1 were asymptomatic. As a result of this investigation, the Alaska Section of Laboratories restricted IgM anti-HAV reflex testing, unless specifically requested, to patients who have symptoms of acute hepatitis indicated on the laboratory-test request form. IgM anti-HAV can often be detected several days before symptom onset and is usually detectable for 3-6 months after illness onset [1] . However, one study showed that IgM anti-HAV persisted for at least 30 months after infection in 2 of 15 patients tested [6] , and persons with persistently positive IgM anti-HAV test results for at least 5 years have been reported in other states [5] . Possible causes include detection of low but clinically irrelevant levels of circulating IgM anti-HAV in persons with previous HAV infections, or cross-reaction with other serum factors or medications.
For 2 persons, the positive IgM anti-HAV test results were most likely caused by a dose of hepatitis A vaccine they received in the weeks before testing. IgM anti-HAV is detectable in 8%-20% of vaccine recipients for 2-3 weeks after hepatitis A vaccination, and has been detected more than 1 month after vaccination [1] . In addition, serologic testing to assess hepatitis A vaccine response is not recommended, because vaccination can engender protective anti-HAV concentrations that are still below the limit of detection for commercially available anti-HAV assays [1] .
Testing for IgM anti-HAV is indicated for persons with illnesses clinically compatible with acute HAV infection, but it is not to be used to assess response to vaccination or to screen asymptomatic persons with no known recent exposure to HAV. As these data from Alaska indicate, IgM anti-HAV testing of persons who do not have evidence of hepatitis A or recent exposure to HAV can lead to positive IgM anti-HAV test results that are irrelevant to clinical care. Furthermore, when patients who do not have clinical or laboratory evidence of acute viral hepatitis receive IgM anti-HAV testing, positive test results may cause unnecessary concerns and costs for patients, misdiagnoses by health care providers, and an additional burden on local health departments, who must assess the need for postexposure prophylaxis for contacts. Although multiple laboratories were involved in this case review, the 0.6% positivity rate for the Alaska Section of Laboratories suggests that nontargeted IgM anti-HAV testing is widespread and constitutes a substantial resource burden. To increase the predictive value of a positive IgM anti-HAV test result, clinicians should limit laboratory testing for acute HAV infection to patients with clinical or epidemiologic indications for testing. Clinicians who do not suspect acute hepatitis A but want to establish whether immunity to HAV is present should be aware that reflex testing practices might result in testing for IgM anti-HAV if test results for total anti-HAV are found to be positive.
Separate panels of tests for determining immunity to HAV and for diagnosing acute hepatitis might reduce inappropriate testing. Individual health care providers may have contracts with laboratories that make panel testing more cost-effective than individual testing. Prices may vary greatly depending on the volume of tests submitted; therefore, general conclusions about the role of cost in determining which test or panel of tests to perform cannot be made. For the Alaska Section of Laboratories, testing is free to the consumer, and the cost for a panel of tests is the sum of the costs for the individual tests; therefore, no savings would result by requesting more tests than necessary.
